Keyphrases
Acute Myeloid Leukemia
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
54%
Venetoclax
36%
Relapsed or Refractory
33%
Leukemia Patients
27%
Chemotherapy
26%
Intensive Chemotherapy
23%
Overall Survival
21%
Acute Lymphoblastic Leukemia
21%
Israel
18%
First Remission
17%
Neutrophil Extracellular Traps
17%
Midostaurin
16%
Complete Remission
16%
Adult Patients
15%
Leukemia
15%
Neutrophils
14%
Hypomethylating Agents
13%
First Complete Remission
12%
Relapsed or Refractory Acute Myeloid Leukemia
12%
FLT3 mutation
12%
Oncology Patients
12%
Tyrosine Kinase Inhibitor
12%
Gilteritinib
12%
Late-onset Neutropenia
12%
Mixed-phenotype Acute Leukemia
12%
Blinatumomab
12%
Meta-analysis
12%
Systematic Meta-analysis
12%
FLAG-Ida
12%
Chronic Granulomatous Disease
12%
Graft-versus-host Disease (GvHD)
11%
Leukemia-lymphoma
11%
Older Adults
11%
Newly Diagnosed
11%
Cytarabine
11%
Pretransplant
10%
Neutropenia
10%
Myeloproliferative Neoplasms
9%
Consolidation Chemotherapy
9%
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
9%
Monotherapy
9%
Human Telomerase Reverse Transcriptase (hTERT)
9%
Bacteremia
8%
Rituximab Therapy
8%
Lymphoma
8%
Non-relapse Mortality
8%
Minimal Residual Disease
8%
High-dose Cytarabine
8%
Extracorporeal Photopheresis
8%
Medicine and Dentistry
Acute Myeloid Leukemia
90%
Cell Transplantation
32%
Hematopoietic Stem Cell
32%
Venetoclax
32%
Overall Survival
23%
Acute Lymphoblastic Leukemia
21%
Disease
18%
Neutropenia
17%
Neutrophil
17%
Infection
14%
Transplantation
13%
Hypomethylating Agent
13%
Azacitidine
12%
Systematic Review
12%
Retrospective Study
12%
Meta-Analysis
12%
Acute Myelogenous Leukemia
12%
Chronic Granulomatous Disease
12%
Diagnosis
12%
Cytarabine
11%
Malignant Neoplasm
10%
Leukemia
10%
Platelet
10%
Bacteremia
10%
Graft Versus Host Reaction
9%
Consolidation Chemotherapy
9%
Hematopoietic Stem Cell Transplantation
9%
Extracellular Trap
9%
Myelodysplastic Syndrome
9%
Midostaurin
8%
Rituximab
8%
Adolescent
8%
Gilteritinib
8%
Maintenance Therapy
8%
Anemia
8%
Telomerase Reverse Transcriptase
8%
Photopheresis
8%
Acute Leukemia
8%
Salvage Therapy
8%
Randomized Controlled Trial
7%
Non-Hodgkin Lymphoma
7%
Infectious Complication
6%
Diffuse Large B-Cell Lymphoma
6%
Drug Megadose
6%
Pediatrics
6%
Allogeneic Hematopoietic Stem Cell Transplantation
6%
Chronic Graft Versus Host Disease
6%
Bloodstream Infection
6%
Minimal Residual Disease
6%
Febrile Neutropenia
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
76%
Chemotherapy
39%
Venetoclax
36%
Remission
29%
Overall Survival
24%
Acute Lymphoblastic Leukemia
18%
Neutropenia
16%
Disease
14%
Cytarabine
14%
Protein Tyrosine Kinase Inhibitor
13%
Azacitidine
13%
Rituximab
12%
Malignant Neoplasm
12%
Acute Leukemia
12%
Blinatumomab
12%
Gilteritinib
12%
Leukemia
11%
Randomized Controlled Trial
9%
Graft Versus Host Reaction
9%
Monotherapy
9%
Midostaurin
9%
Adverse Event
8%
Retrospective Study
8%
Methotrexate
8%
C Reactive Protein
8%
Thrombopoietin Receptor
8%
Chimeric Antigen Receptor
8%
Infection
7%
Bacteremia
6%
Neoplasm
6%
Chronic Graft Versus Host Disease
6%
Infectious Complication
6%
Febrile Neutropenia
6%
Telomerase Reverse Transcriptase
6%
Cohort Study
5%
Myeloproliferative Neoplasm
5%
Antiinfective Agent
5%
Bloodstream Infection
5%
Sorafenib
5%